Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Mechanical properties and degradation of drug eluted bioresorbable vascular scaffolds prepared by three-dimensional printing technology.

Zhang Y, Zhao J, Yang G, Zhou Y, Gao W, Wu G, Li X, Mao C, Sheng T, Zhou M.

J Biomater Sci Polym Ed. 2019 Mar 21:1-14. doi: 10.1080/09205063.2019.1586303. [Epub ahead of print]

PMID:
30897033
2.

Degree of bioresorbable vascular scaffold expansion modulates loss of essential function.

Ferdous J, Kolachalama VB, Kolandaivelu K, Shazly T.

Acta Biomater. 2015 Oct;26:195-204. doi: 10.1016/j.actbio.2015.08.009. Epub 2015 Aug 12.

3.

Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.

Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, Kastrati A.

Lancet. 2016 Feb 6;387(10018):537-44. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17. Review.

PMID:
26597771
4.

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.

Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM.

Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.

PMID:
21098436
5.

Effect of vascular scaffold composition on release of sirolimus.

Jelonek K, Jaworska J, Pastusiak M, Sobota M, Włodarczyk J, Karpeta-Jarzabek P, Kaczmarczyk B, Kasperczyk J, Dobrzyński P.

Eur J Pharm Biopharm. 2018 Nov;132:41-49. doi: 10.1016/j.ejpb.2018.08.015. Epub 2018 Sep 1.

PMID:
30179737
6.

Strength reliability and in vitro degradation of three-dimensional powder printed strontium-substituted magnesium phosphate scaffolds.

Meininger S, Mandal S, Kumar A, Groll J, Basu B, Gbureck U.

Acta Biomater. 2016 Feb;31:401-411. doi: 10.1016/j.actbio.2015.11.050. Epub 2015 Nov 30.

PMID:
26621692
7.

Late positive remodeling and late lumen gain contribute to vascular restoration by a non-drug eluting bioresorbable scaffold: a four-year intravascular ultrasound study in normal porcine coronary arteries.

Strandberg E, Zeltinger J, Schulz DG, Kaluza GL.

Circ Cardiovasc Interv. 2012 Feb 1;5(1):39-46. doi: 10.1161/CIRCINTERVENTIONS.111.964270. Epub 2012 Jan 17.

PMID:
22253358
8.

[Mechanical properties of polylactic acid/beta-tricalcium phosphate composite scaffold with double channels based on three-dimensional printing technique].

Lian Q, Zhuang P, Li C, Jin Z, Li D.

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2014 Mar;28(3):309-13. Chinese.

PMID:
24844010
9.

Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.

Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B investigators.

Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12. doi: 10.1002/ccd.22864. Epub 2011 Mar 16.

PMID:
21413120
10.

Bioresorbable Vascular Scaffolds - Are We Facing a Time of Crisis or One of Breakthrough?

Kang J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS.

Circ J. 2017 Jul 25;81(8):1065-1074. doi: 10.1253/circj.CJ-17-0152. Epub 2017 Jul 6. Review.

11.

Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA.

JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.

12.

Mechanical behavior of polymer-based vs. metallic-based bioresorbable stents.

Ang HY, Huang YY, Lim ST, Wong P, Joner M, Foin N.

J Thorac Dis. 2017 Aug;9(Suppl 9):S923-S934. doi: 10.21037/jtd.2017.06.30. Review.

13.

Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.

Tenekecioglu E, Serruys PW, Onuma Y, Costa R, Chamié D, Sotomi Y, Yu TB, Abizaid A, Liew HB, Santoso T.

JACC Cardiovasc Interv. 2017 Jun 12;10(11):1115-1130. doi: 10.1016/j.jcin.2017.03.015. Epub 2017 May 17.

14.

[Study on the preparation of polycaprolactone/type collagen tissue engineered meniscus scaffold by three-dimensional printing and its physiochemical properties].

Shen S, Chen M, Gao S, Guo W, Wang Z, Li H, Li X, Zhang B, Xian H, Zhang X, Liu S, Hao L, Zhuo N, Guo Q.

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2018 Sep 15;32(9):1205-1210. doi: 10.7507/1002-1892.201803074. Chinese.

PMID:
30129332
15.

Three-dimensional (3D) printed scaffold and material selection for bone repair.

Zhang L, Yang G, Johnson BN, Jia X.

Acta Biomater. 2019 Jan 15;84:16-33. doi: 10.1016/j.actbio.2018.11.039. Epub 2018 Nov 24. Review.

PMID:
30481607
16.

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.

Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S.

J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017.

17.

The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.

Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, Ormiston JA, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Tijssen JG, Wykrzykowska JJ, de Winter RJ, Chevalier B, Serruys PW, Onuma Y.

JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-42. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.

18.

Absorb Bioresorbable Vascular Scaffold in Complex Coronary Bifurcation Interventions: Insights From an In Vivo Multimodality Imaging Study.

Bennett J, Vanhaverbeke M, Vanden Driessche N, Adriaenssens T, Hiltrop N, Desmet W, Sinnaeve P, Dubois C.

Circ Cardiovasc Interv. 2016 Aug;9(8). pii: e003849. doi: 10.1161/CIRCINTERVENTIONS.116.003849.

PMID:
27512090
19.

Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).

Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M.

JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005. Erratum in: JACC Cardiovasc Interv. 2015 Mar;8(3):503.

20.

The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.

Rizik DG, Hermiller JB, Kereiakes DJ.

Catheter Cardiovasc Interv. 2015 Oct;86(4):664-77. doi: 10.1002/ccd.26172. Review.

PMID:
26386235

Supplemental Content

Support Center